NCT07232654

Iparomlimab/Tuvonralimab Injection Plus CCRT in LACC

A Clinical Study to Evaluate the Safety and Efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: Female
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is a clinical study to evaluate the safety and efficacy of Iparomlimab/Tuvonralimab Injection (QL1706, a Bifunctional Mabpair Product of Anti-PD-1 and Anti-CTLA-4 Antibodies) in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.

Conditions

• LOCALLY ADVANCED CERVICAL CANCERS

Interventions

Type	Name	Description
DRUG	Iparomlimab/Tuvonralimab	IV infusion
DRUG	Cisplatin	IV infusion
RADIATION	Brachytherapy and External Beam Radiotherapy	Radiation

Timeline

• Start date: 2025-11-11
• Primary completion: 2027-11-30
• Completion: 2028-02-28
• First posted: 2025-11-18
• Last updated: 2025-12-01

Locations

1 site across 1 country: China